StockNews.AI
ABEO
StockNews.AI
50 days

Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index

1. ABEO added to Russell 2000 and Russell 3000 indexes today. 2. Inclusion follows FDA approval of ZEVASKYN™, boosting investor visibility. 3. Russell indexes manage $10.6 trillion in assets, enhancing ABEO's market access. 4. ZEVASKYN™ is the first autologous cell-based gene therapy for RDEB. 5. Abeona aims to launch ZEVASKYN™ commercially as a pivotal growth strategy.

7m saved
Insight
Article

FAQ

Why Bullish?

Inclusion in major indexes typically drives stock demand and enhances visibility among institutional investors.

How important is it?

The article highlights key metrics related to investment potential and visibility; index inclusion significantly affects stock performance.

Why Short Term?

Immediate effect expected from investor interest post-announcement; medium-term success dependent on ZEVASKYN™ commercialization.

Related Companies

Russell 2000Russell 3000
June 30, 2025 07:30 ET  | Source: Abeona Therapeutics Inc. CLEVELAND, June 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it was added as a member of the U.S. small-cap Russell 2000® Index and the broad-market Russell 3000® Index as part of the reconstitution of the Russell stock indexes, effective at the open of the U.S. equity markets today. “Abeona's addition to the Russell 2000 and 3000 indexes, on the heels of ZEVASKYN™'s FDA approval, represents a pivotal moment for the company,” said Joe Vazzano, Chief Financial Officer of Abeona. “This inclusion amplifies our positive momentum as we progress with ZEVASKYN's commercial launch and provides an opportunity to engage with a broader audience of investors.” Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell U.S. indexes, which belong to FTSE Russell, the global index provider. Membership in the Russell 3000® Index means automatic inclusion in either the large-cap Russell 1000® Index or small-cap Russell 2000® Index, as well as the appropriate growth and value style indexes. The Russell 3000® Index encompasses the 3,000 largest U.S.-traded stocks by objective, market-capitalization rankings, and style attributes. Membership in these indexes is updated annually and remains in place for one year. For more information on the Russell 2000® and Russell 3000® Indexes and the Russell U.S. Indexes Reconstitution, visit the “Russell Reconstitution” section on the FTSE Russell website. About Abeona TherapeuticsAbeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN™ (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com. ZEVASKYNTM, Abeona AssistTM, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc. Forward-Looking Statements This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to commercialize ZEVASKYN, the therapeutic potential of ZEVASKYN, whether the unmet need and market opportunity for ZEVASKYN are consistent with the Company’s expectations, continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with and inspections from the FDA or other regulatory agencies, including those relating to preclinical programs; the ability to achieve or obtain necessary regulatory approvals; the impact of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws. Contact Data Investor and Media Contact: Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics

Related News